Biogen (BSP:BIIB34) Goodwill-to-Asset

: 0.23 (As of Mar. 2023)

View and export this data going back to 2016. Start your Free Trial

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Biogen's Goodwill for the quarter that ended in Mar. 2023 was R$29,959 Mil. Biogen's Total Assets for the quarter that ended in Mar. 2023 was R$128,123 Mil. Therefore, Biogen's Goodwill to Asset Ratio for the quarter that ended in Mar. 2023 was 0.23.

Biogen Goodwill-to-Asset Historical Data

The historical data trend for Biogen's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Goodwill-to-Asset

0.23

0.21

0.23

0.24

0.23

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Goodwill-to-Asset																0.24	0.23	0.23	0.23	0.23

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Biogen Goodwill-to-Asset Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Biogen's Goodwill-to-Asset falls in comparison to its industry or sector. The grey bar indicates the Goodwill-to-Asset's extreme value range as defined by GuruFocus.

Biogen Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Biogen's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Goodwill to Asset (A: Dec. 2022 )	=	Goodwill	/	Total Assets
	=	30155.805	/	128796.076
	=	0.23

Biogen's Goodwill to Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

Goodwill to Asset (Q: Mar. 2023 )	=	Goodwill	/	Total Assets
	=	29958.825	/	128123.226
	=	0.23

Biogen (BSP:BIIB34) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.

Biogen Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Biogen's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BSP:BIIB34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Goodwill-to-Asset

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BSP:BIIB34) Headlines

No Headlines